SAN DIEGO AND VANCOUVER, Sept. 5, 2013 /PRNewswire/ - Sophiris Bio Inc.
(NASDAQ: SPHS, TSX: SHS) (the "Company" or "Sophiris"), a
biopharmaceutical company developing a clinical stage, targeted
treatment for the symptoms of benign prostatic hyperplasia (BPH or
enlarged prostate), today announced that Randall E. Woods, President
and Chief Executive Officer, will present a corporate overview at the
Stifel Healthcare Conference 2013 at the Four Seasons Hotel in Boston,
Massachusetts. The presentation is scheduled for Thursday, September
12, 2013 at 2:05 pm ET.
The presentation will be webcast live and can be accessed through the
Investor Relations page at www.sophiris.com. A replay of the presentation will be available on the Company's
website for 90 days.
Sophiris Bio Inc. is a biopharmaceutical company developing a
clinical-stage, targeted treatment for the symptoms of benign prostatic
hyperplasia (BPH or enlarged prostate), which it believes is an
unsatisfied market with significant market potential. Sophiris' lead
candidate for BPH, PRX302, is designed to be as efficacious as
pharmaceuticals, less invasive than the surgical interventions, and
without the sexual side effects seen with existing treatments. Sophiris
is planning to begin a Phase 3 clinical trial of PRX302 in the second
half of 2013.
For more information, please visit www.sophiris.com.
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by such statements, and therefore these statements should not
be read as guarantees of future performance or results. All
forward-looking statements are based on Sophiris' current beliefs as
well as assumptions made by and information currently available to
Sophiris and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments,
market acceptance and future commitments. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
Sophiris in its public securities filings; actual events may differ
materially from current expectations. Sophiris disclaims any intention
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
SOURCE Sophiris Bio, Inc.